BiotechTube

Tildrakizumab 100 mg + Placebo

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Genital Psoriasis

Conditions

Moderate to Severe Genital Psoriasis

Trial Timeline

Mar 21, 2025 → Feb 1, 2027

NCT ID
NCT06611163

About Tildrakizumab 100 mg + Placebo

Tildrakizumab 100 mg + Placebo is a phase 3 stage product being developed by Sun Pharmaceutical for Moderate to Severe Genital Psoriasis. The current trial status is active. This product is registered under clinical trial identifier NCT06611163. Target conditions include Moderate to Severe Genital Psoriasis.

What happened to similar drugs?

7 of 20 similar drugs in Moderate to Severe Genital Psoriasis were approved

Approved (7) Terminated (2) Active (12)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
🔄CT-P17 + EU-approved HumiraCelltrionPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄CS-3150Daiichi SankyoPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06611163Phase 3Active

Competing Products

20 competing products in Moderate to Severe Genital Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
E6007 + PlaceboEisaiPhase 2
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
35
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
40